Glenmark In Pact With Novartis For Three Respiratory Drugs In Brazil
The deal with Novartis will strengthen Glenmark’s respiratory franchise in Brazil, says chairman Glenn Saldanha.
Drugmaker Glenmark Pharmaceuticals Ltd. on Monday said that its subsidiary Glenmark Farmacutica has entered into an exclusive partnership with Novartis Biosciences SA for three respiratory products in Brazil.
The respiratory products that will be produced under the Glenmark-Novartis deal are Seebri (Glycopyrronium bromide), Onbrize (Indacaterol) and Ultibro (combination of Indacaterol and Glycopyrronium), which are indicated for relief of symptoms in adults with chronic obstructive pulmonary disease.
Under the terms of the deal, Novartis will remain the holder of the registration of these medicines and will be responsible to manufacture them with all technical excellence in line with its global commitment to quality, effectiveness and safety, Glenmark said in a regulatory filing.
Glenmark will be responsible for promoting, commercialising and distributing of these products in Brazil, the company added.
This Glenmark-Novartic deal will be effective from July 1, 2019.
According to Glenn Saldanha, chairman and managing director of Glenmark Pharma, this arrangement with Novartis will strengthen its respiratory franchise in Brazil.
"This partnership is in line with our vision to expand our respiratory product offerings for patients and prescribers in Brazil and further consolidate our position in this segment," Saldanha said.